Literature DB >> 15563013

Autism and tuberous sclerosis.

Max Wiznitzer1.   

Abstract

The co-occurrence of autism spectrum disorder and tuberous sclerosis complex has been recognized for decades. The prevalence of tuberous sclerosis complex in the autism spectrum disorder population is 1 to 4%, whereas features of autism spectrum disorder are present in 25 to 50% of individuals with tuberous sclerosis complex. The underlying reason for this association might be a nonspecific disruption of brain function owing to tuberous sclerosis complex, including tuber location, seizures and their effect on brain development, cognitive impairment, a disturbance in brain development in regions associated with autism spectrum disorder, or, less likely, a linkage between a TSC gene and an autism susceptibility gene. Awareness of the relationship between autism spectrum disorder and tuberous sclerosis complex is important during the evaluation of individuals with either disorder. Better delineation of the association and its causative factors is needed for the development of possible interventions.

Entities:  

Mesh:

Year:  2004        PMID: 15563013     DOI: 10.1177/08830738040190090701

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  56 in total

Review 1.  Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway.

Authors:  E Carla Parker-Athill; Jun Tan
Journal:  Neurosignals       Date:  2010-10-02

Review 2.  Annual Research Review: Development of the cerebral cortex: implications for neurodevelopmental disorders.

Authors:  John L R Rubenstein
Journal:  J Child Psychol Psychiatry       Date:  2010-08-24       Impact factor: 8.982

Review 3.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

4.  The parvalbumin/somatostatin ratio is increased in Pten mutant mice and by human PTEN ASD alleles.

Authors:  Daniel Vogt; Kathleen K A Cho; Anthony T Lee; Vikaas S Sohal; John L R Rubenstein
Journal:  Cell Rep       Date:  2015-04-30       Impact factor: 9.423

Review 5.  The role of immune dysfunction in the pathophysiology of autism.

Authors:  Charity Onore; Milo Careaga; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2011-08-28       Impact factor: 7.217

Review 6.  The autism diagnosis in translation: shared affect in children and mouse models of ASD.

Authors:  Somer L Bishop; Garet P Lahvis
Journal:  Autism Res       Date:  2011-08-31       Impact factor: 5.216

7.  Alterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide.

Authors:  Gregory L Holmes; Chengju Tian; Amanda E Hernan; Sean Flynn; Devon Camp; Jeremy Barry
Journal:  Neurobiol Dis       Date:  2015-03-10       Impact factor: 5.996

8.  Using zebrafish to assess the impact of drugs on neural development and function.

Authors:  Su Guo
Journal:  Expert Opin Drug Discov       Date:  2009-07-01       Impact factor: 6.098

Review 9.  mTOR signaling: at the crossroads of plasticity, memory and disease.

Authors:  Charles A Hoeffer; Eric Klann
Journal:  Trends Neurosci       Date:  2009-12-04       Impact factor: 13.837

10.  Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice.

Authors:  Jing Zhou; Jacqueline Blundell; Shiori Ogawa; Chang-Hyuk Kwon; Wei Zhang; Christopher Sinton; Craig M Powell; Luis F Parada
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.